(Q45226599)

11 December 2017

title

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer (English)

1 reference

11 December 2017

1 reference

Y Ohe

1

1 reference

11 December 2017

S Negoro

2

1 reference

11 December 2017

K Matsui

3

1 reference

11 December 2017

K Nakagawa

4

1 reference

11 December 2017

T Sugiura

5

1 reference

11 December 2017

Y Takada

6

1 reference

11 December 2017

Y Nishiwaki

7

1 reference

11 December 2017

S Yokota

8

1 reference

11 December 2017

M Kawahara

9

1 reference

11 December 2017

N Saijo

10

1 reference

11 December 2017

M Fukuoka

11

1 reference

11 December 2017

Y Ariyoshi

12

1 reference

11 December 2017

publication date

14 January 2005

1 reference

11 December 2017

1 reference

11 December 2017

volume

16

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

430-436

1 reference

Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Hematological aspects of a novel 9-aminoanthracycline, amrubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Epirubicin in extensive small-cell lung cancer: a phase II study in previously untreated patients: a National Cancer Institute of Canada Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

Results of recent Japanese clinical trials in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI081

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDI081

1 reference

11 December 2017

1 reference